Dr. Klute is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
42nd And Emile
Omaha, NE 68198
Summary
- Dr. Kelsey Klute is an oncologist in Omaha, NE and is affiliated with multiple hospitals in the area, including Nebraska Medical Center (UNMC) and Nebraska Medicine - Nebraska Medical Center. She received her medical degree from University of North Dakota School of Medicine and Health Sciences and has been in practice 7 years. She specializes in hematologic oncology.
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2013 - 2016
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2010 - 2013
- University of North Dakota School of Medicine and Health SciencesClass of 2010
Certifications & Licensure
- NE State Medical License 2016 - 2026
- NY State Medical License 2013 - 2016
- MO State Medical License Active through 2013
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer Start of enrollment: 2021 Jun 16
- Pancreatic Cancer Early Detection Consortium Start of enrollment: 2020 Sep 18
Roles: Principal Investigator
Publications & Presentations
PubMed
- Single-cell RNA-sequencing of human spleens reveals an IDO-1tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individuals.Clara S Mundry, Aleata A Triplett, Osama Shiraz Shah, Vijender Chaitankar, Kyle L McAndrews
Cancer Letters. 2024-12-28 - MUC16 Retention after Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma.Kathryn M Muilenburg, Evie G Ehrhorn, Madeline T Olson, Carly C Isder, Kelsey A Klute
Cancers. 2024-10-10 - Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.Timothy L Cannon, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vi K Chiu
Journal of Clinical Oncology. 2024-09-20
Lectures
- Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- #earlydetection: Leveraging social media to recruit individuals at increased-risk of pancreas cancer for an early detection study.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
- RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical TrialAugust 14th, 2024
- RenovoRx Expands Enrollment in TIGeR-PaC Pivotal TrialAugust 14th, 2024
- University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical TrialJune 26th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: